Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.77 |
| ▸ | NPC1 | O15118 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.77 |
| ▸ | MTOR | P42345 | 2/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | MLNR | O43193 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | ESR1 | P03372 | 1/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.77 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.77 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.77 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL5146578 | 0.93 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL5146585 | 0.93 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL29248769 | 0.92 | SLC6A4 (0.87) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL3022459 | 0.91 | SLC6A4 (0.85) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL1206649 | 0.91 | SLC6A4 (0.85) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL6284080 | 0.91 | MEN1 (0.88) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL7933194 | 0.90 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL3786157 | 0.90 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL6700902 | 0.90 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL6442184 | 0.90 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626950-A4 | SERTRALINE COMPOSITIONS | TRANSFORM PHARMACEUTICALS INC (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1736150-A2 | Sertraline salts and sustained-release dosage forms of sertraline | Pfizer, Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1626950-A1 | SERTRALINE COMPOSITIONS | Transform Pharmaceuticals, Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| US-6899896-B2 | Hydrogel-driven layered drug dosage form | PFIZER INC (US) | 2005-05-31 | — | — | US | claimed |
| US-20050014829-A1 | Sertraline compositions | TRANSFORM PHARMACEUTICALS, INC. | 2005-01-20 | — | — | US | claimed |
| WO-2005000786-A1 | SERTRALINE COMPOSITIONS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | claimed |
| US-20040208926-A1 | Solubilized sertraline compositions | PFIZER INC | 2004-10-21 | — | — | US | claimed |
| JP-2003518487-A | — | — | 2003-06-10 | — | — | JP | claimed |
| US-6517866-B1 | Oral administration at controlled rate; side effect reduction | PFIZER INC. | 2003-02-11 | — | — | US | claimed |
| EP-1239839-A2 | HYDROGEL-DRIVEN LAYERED DRUG DOSAGE FORM COMPRISING SERTRALINE | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | claimed |
| US-20010044474-A1 | Hydrogel-driven layered drug dosage form | BEND RESEARCH, INC. | 2001-11-22 | — | — | US | claimed |
| WO-2001047498-A2 | HYDROGEL-DRIVEN LAYERED DRUG DOSAGE FORM COMPRISING SERTRALINE | PFIZER PRODUCTS INC. (US) | 2001-07-05 | — | — | WO | claimed |
| JP-2000514101-A | — | — | 2000-10-24 | — | — | JP | claimed |
| CN-1261793-A | Sertraline salts and sustained release dosage forms of sertraline | PFIZER (US) | 2000-08-02 | — | — | CN | claimed |
| EP-0999830-A1 | SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE | PFIZER INC. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999001121-A1 | SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE | PFIZER INC. (US) | 1999-01-14 | — | — | WO | claimed |
| US-9457095-B2 | Pharmaceutical compositions providing enhanced drug concentrations | BEND RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150190518-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | BEND RESEARCH, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| WO-1999001121-A1 | SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE | PFIZER INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| WO-1999001120-A1 | SOLUBILIZED SERTRALINE COMPOSITIONS | PFIZER PRODUCTS INC. (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014829-A1 | Sertraline compositions | SUCNR1, TST, SORD | SLC6A4 66/4885SLC6A2 166/4885SLC6A3 313/4885 |
| US-20010044474-A1 | Hydrogel-driven layered drug dosage form | HTR3D, HTR5A, HTR3A | SLC6A4 5/4885SLC6A2 21/4885SLC6A3 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.